Summary
Thermo Fisher Scientific Inc. reported solid financial results for the nine months ended September 30, 2017, demonstrating growth driven by strategic acquisitions and organic demand. Total revenues increased by 12% year-over-year to $14.87 billion, with significant contributions from the recent acquisition of Patheon. The company's operating income saw an 18% increase, reflecting successful integration and operational efficiencies. Financially, the company maintained a strong liquidity position, with substantial cash flow from operations and available borrowing capacity. While debt levels increased due to acquisitions, the company's covenants remain within manageable limits, and its ability to service debt appears sound. Investors can take comfort in the company's strategic growth initiatives and its consistent performance across its diverse business segments.
Key Highlights
- 1Total revenues grew 12% to $14.87 billion for the first nine months of 2017, compared to $13.32 billion in the prior year, driven significantly by acquisitions.
- 2Operating income increased by 18% to $2.01 billion for the first nine months of 2017, compared to $1.70 billion in the prior year, indicating improved profitability.
- 3The company successfully integrated major acquisitions, notably Patheon, which contributed to a 15% revenue increase in the Laboratory Products and Services segment.
- 4Cash flow from operating activities remained robust, totaling $2.14 billion for the first nine months of 2017, providing ample liquidity.
- 5Despite an increase in debt levels to fund acquisitions, the company maintained a healthy balance sheet and sufficient borrowing capacity.
- 6The Analytical Instruments segment showed strong performance with a 39% revenue increase for the nine-month period, largely due to acquisitions.
- 7Strategic growth investments are ongoing, with the company focusing on expanding commercial capabilities and enhancing customer experience.